We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+25.06%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$288M
AUM Growth
+$45.4M
Cap. Flow
+$18.1M
Cap. Flow %
6.29%
Top 10 Hldgs %
61.77%
Holding
53
New
11
Increased
10
Reduced
18
Closed
13

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$7.63M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$5.58M
3
HROW icon
Harrow
HROW
+$5.15M
4
KALV
KalVista Pharmaceuticals
KALV
+$4.95M
5
PHAT icon
Phathom Pharmaceuticals
PHAT
+$4.3M

Top Sells

Rank Stock Value
1
CUTR
Cutera, Inc.
CUTR
+$6.74M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$5.25M
3
MRUS
Merus
MRUS
+$5.07M
4
KROS icon
Keros Therapeutics
KROS
+$3.89M
5
MRSN
Mersana Therapeutics
MRSN
+$2.98M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNS
26
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.29M 1.14%
+826,200
New +$4.06M
FOCL
27
EDAP TMS S.A.
FOCL
$199M
$3.27M 1.14%
306,713
+235,413
+330% +$2.31M
WHWK
28
Whitehawk Therapeutics
WHWK
$278M
$3.23M 1.12%
+252,046
New +$3.29M
MOR
29
DELISTED
MorphoSys AG American Depositary Shares
MOR
$3.21M 1.12%
896,600
+775,585
+641% +$3.47M
MRSN
30
DELISTED
Mersana Therapeutics
MRSN
$2.7M 0.94%
18,400
-17,612
-49% -$2.98M
THRX
31
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$2.66M 0.93%
535,000
+314,350
+142% +$1.84M
FENC icon
32
Fennec Pharmaceuticals
FENC
$413M
$2.61M 0.91%
+272,200
New +$2.41M
IDYA icon
33
IDEAYA Biosciences
IDYA
$4.03B
$2.52M 0.88%
138,800
+137,300
+9,153% +$2.31M
STXS icon
34
Stereotaxis
STXS
$147M
$2.45M 0.85%
1,185,000
-371,800
-24% -$727K
BCAB icon
35
BioAtla
BCAB
$5.23M
$2.16M 0.75%
+5,236
New +$2.17M
FBIO icon
36
Fortress Biotech
FBIO
$93.4M
$1.34M 0.47%
136,667
-63,266
-32% -$700K
ALLK
37
DELISTED
Allakos
ALLK
$1.29M 0.45%
153,500
– –
TBPH icon
38
Theravance Biopharma
TBPH
$885M
$983K 0.34%
+87,600
New +$921K
TRVI icon
39
Trevi Therapeutics
TRVI
$2.56B
$936K 0.33%
+485,000
New +$956K
MODD icon
40
Modular Medical
MODD
$29.4M
$490K 0.17%
8,167
-1,014
-11% -$91.3K
BLRX
41
BioLineRX
BLRX
$12.1M
– –
-417
Closed -$16K
DERM icon
42
Journey Medical
DERM
$213M
– –
-259,293
Closed -$638K
MGTX icon
43
MeiraGTx Holdings
MGTX
$1.36B
– –
-10,000
Closed -$84K
MRUS
44
DELISTED
Merus
MRUS
– –
-253,200
Closed -$5.07M
NGNE icon
45
Neurogene
NGNE
$758M
– –
-28,750
Closed -$368K
NPCE icon
46
Neuropace
NPCE
$485M
– –
-116,324
Closed -$436K
OPTN
47
DELISTED
OptiNose
OPTN
– –
-6,065
Closed -$333K
LENZ
48
LENZ Therapeutics
LENZ
$151M
– –
-82,464
Closed -$1.83M
CMRX
49
DELISTED
Chimerix, Inc.
CMRX
– –
-365,000
Closed -$704K
CUTR
50
DELISTED
Cutera, Inc.
CUTR
– –
-147,700
Closed -$6.74M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2022 Portfolio in Review

As of Q4 2022, Opaleye Management held 53 positions worth $288M, up 19% from $242M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Opaleye Management deployed $18.1M of net new capital in Q4 2022, opening 11 new positions and adding to 10 existing holdings. Its largest new stake was Biohaven: 540,000 shares worth $7.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $3.89M trimmed.

  • Opaleye Management's largest Q4 2022 buy was Biohaven: 540,000 shares worth $7.5M.
  • Opaleye Management added most to Harrow in Q4 2022, an estimated $5.15M increase.
  • Opaleye Management's biggest Q4 2022 reduction was Keros Therapeutics, cutting an estimated $3.89M.
  • Opaleye Management fully exited Cutera, Inc. in Q4 2022, selling an estimated $6.74M.
  • Opaleye Management's ten largest holdings make up 62% of its $288M portfolio in Q4 2022.
  • Opaleye Management opened 11 new positions and closed 13 in Q4 2022.
  • Opaleye Management's portfolio value rose 19% quarter-over-quarter to $288M.

Based on Opaleye Management's 13F filing for Q4 2022, filed 10 Feb 2023.